Stock ACHFF ARCH BIOPARTNERS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Arch Biopartners Inc.

Equities

ACHFF

CA03938C1041

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 16:49:52 25/06/2024 BST 		5-day change 1st Jan Change
1.22 USD +3.39% Intraday chart for Arch Biopartners Inc. -0.81% +9.27%
06-18 Arch Biopartners Obtains University of Calgary Ethics Approval to Proceed with Phase II Trial MT
06-18 Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) CI

Valuation

Fiscal Period: September 2021 2024 2025
Capitalization 1 106.9 106.4 -
Enterprise Value (EV) 1 106.9 106.4 106.4
P/E ratio -90.8 x -23.8 x -23.8 x
Yield - - -
Capitalization / Revenue - 53.2 x 53.2 x
EV / Revenue - 53.2 x 53.2 x
EV / EBITDA - -21.3 x -8.86 x
EV / FCF - - -
FCF Yield - - -
Price to Book - - -
Nbr of stocks (in thousands) 61,962 63,851 -
Reference price 2 1.725 1.666 1.666
Announcement Date 28/01/22 - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2021 2022 2023 2024 2025
Net sales 1 - - - 2 2
EBITDA 1 - - - -5 -12
EBIT - -1.389 - - -
Operating Margin - - - - -
Earnings before Tax (EBT) - - - - -
Net income -1.17 - -3.327 - -
Net margin - - - - -
EPS 2 -0.0190 - - -0.0700 -0.0700
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 28/01/22 30/01/23 29/01/24 - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2023 Q1 2023 Q2 2023 Q3 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3
Net sales 0.4347 2.531 0.1164 - - - - - - -
EBITDA - - - - - - - - - -
EBIT -2.211 -0.896 -0.4743 - - - - - - -
Operating Margin -508.54% -35.4% -407.59% - - - - - - -
Earnings before Tax (EBT) -2.158 -0.9624 -0.4508 - - - - - - -
Net income -2.158 -0.9624 -0.4508 -0.7832 - - - - - -
Net margin -496.37% -38.02% -387.37% - - - - - - -
EPS 1 -0.0350 -0.0150 -0.007000 - -0.0180 -0.0200 -0.0200 -0.0200 -0.0200 -0.0200
Dividend per Share - - - - - - - - - -
Announcement Date 01/03/23 30/05/23 29/08/23 29/02/24 31/05/24 - - - - -
1CAD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2021 2023 2024 2025
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - - -
ROE (net income / shareholders' equity) - - - -
ROA (Net income/ Total Assets) - - - -
Assets - - - -
Book Value Per Share - - - -
Cash Flow per Share - - - -
Capex - - - -
Capex / Sales - - - -
Announcement Date 28/01/22 29/01/24 - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.22
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ARCH BIOPARTNERS INC. Stock Arch Biopartners Inc.
+9.27% 77.9M
MODERNA, INC. Stock Moderna, Inc.
+38.36% 52.73B
LONZA GROUP AG Stock Lonza Group AG
+38.71% 39B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.63% 38.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+25.46% 30.38B
CELLTRION, INC. Stock Celltrion, Inc.
-11.17% 26.39B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.44% 26.08B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+45.09% 14.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.93% 12.6B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-5.30% 11.51B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ACHFF Stock
  4. Financials Arch Biopartners Inc.